Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:86

Article

Blauvelt, Andrew¹  Shi, Nianwen²  Somani, Najwa³  Burge, Russel^3,4  Zhu, Baojin³  Ridenour, Terri L.³  Lew, Carolyn R.²  Zimmerman, Nicole M.²  Atiya, Bilal³  Murage, Mwangi J.³ 

[1] Oregon Med Res Ctr, Portland, OR USA

[2] IBM Watson Hlth, Cambridge, MA USA

[3] Eli Lilly & Co, Indianapolis, IN 46221 USA

[4] Univ Cincinnati, Cincinnati, OH 45221 USA

关键词: dosing;    ixekizumab;    psoriasis;    secukinumab;    treatment adherence;    treatment discontinuation;    treatment persistence;    treatment reinitiation;    treatment switching;   

DOI  :  10.1016/j.jaad.2021.06.878

来源: Elsevier

【 摘 要 】

Background: Real-world data on long-term treatment patterns associated with interleukin-17A inhibitors in plaque psoriasis are lacking. Objective: To compare ixekizumab or secukinumab treatment patterns over a 24-month period among plaque psoriasis patients. Methods: Adult patients with psoriasis who had 1 or more claims for ixekizumab or secukinumab between March 1, 2016, and October 31, 2019, and with 24 months of follow-up after starting treatment were identified from IBM MarketScan claims databases. Inverse probability of treatment weighting and multivariable models were employed to balance cohorts and estimate the risks of nonpersistence, discontinuation, and switching and odds of highly adherent treatment (proportion of days covered >= 80%). Results: A total of 471 ixekizumab and 990 secukinumab users were included. Compared to secukinumab, ixekizumab use was associated with a 20% lower risk of nonpersistence (hazard ratio, 0.80; 95% CI, 0.70-0.92), a 17% lower risk of discontinuation (hazard ratio, 0.83; 95% CI, 0.72-0.96), and a 42% higher odds of being highly adherent to treatment (odds ratio, 1.42; 95% CI, 1.12-1.80). No difference in risk of switching was observed (hazard ratio, 0.83; 95% CI, 0.68-1.01). Limitations: Disease severity and clinical outcomes were unavailable. Conclusion: Over 24 months, ixekizumab users exhibited better persistence and adherence, and a lower risk of discontinuation than secukinumab users in real-world settings.

【 授权许可】

Free